Pertuzumab
Pertuzumab (also called 2C4 and Omnitarg®) is a monoclonal antibody, the first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[1] Omnitarg is a brand name of Genentech.
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[2]
References
- ^ a b de Bono, Johann S. (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology. 25 (3): 257–262.
- ^ Genentech press release - May 15, 2005